Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Subjects

Subjects :

CD30 positive
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
Hematology
CHOP
medicine.disease
Peripheral T-cell lymphoma
Double blind
Internal medicine
Medicine
business
Brentuximab vedotin
medicine.drug

Details

Language :

English

Database :

OpenAIRE

Journal :

Iyer, S, Trümper, L, O’Connor, O A, Pro, B, Illidge, T, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Menne, T, Belada, D, Illès, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M, Puhlmann, M & Horwitz, S 2021, ' Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma ', Clinical Lymphoma Myeloma and Leukemia, vol. 21, no. Suppl. 1, pp. S203 . https://doi.org/10.1016/S2152-2650(21)01276-3

Accession number :

edsair.doi.dedup.....a6af2bf6e2b0fc1723ba90fb1b630d44